Literature DB >> 26753957

High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer.

Jianlong Li1, Longwang Wang1, Ruihai Xiao1, Qiufeng Pan1, Hongwei Huang1, Renrui Kuang2.   

Abstract

The present study was to investigate the expression and prognostic value of constitutive photomorphogenic 1 (COP1) in bladder cancer. In our study, real-time quantitative PCR (RT-PCR) was performed to detect 10 pairs of fresh bladder cancer (BCa) and adjacent noncancerous tissues. In addition, immunohistochemistry was utilized to detect the expression of COP1 in 174 clinical bladder cancer samples. What is more, the correlation of COP1 expression and clinicopathological features and clinical outcomes were analyzed. The expression levels of COP1 in clinical bladder cancer were much higher than that in paired adjacent noncancerous tissues (p < 0.0001). High expression of COP1 was closely related with differentiation (p = 0.040) and recurrence (p = 0.001) of patients with bladder cancer. Kaplan-Meier analysis revealed that the expression of COP1 was closely correlated with overall survival (p = 0.048) of bladder cancer, while, recurrence-free survival (p = 0.201). Moreover, Cox multivariate regression analyses showed that COP1 expression was an independent predictor of overall survival (OS; p = 0.027, hazard ratio = 2.127, confidence interval 0.814 to 9.736). Based on our data, the present study suggests that high expression of COP1 may be a novel biological indicator for evaluation of poor prognosis in bladder cancer.

Entities:  

Keywords:  Bladder cancer; COP1 expression; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 26753957     DOI: 10.1007/s13277-015-4765-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  Good COP1 or bad COP1? In vivo veritas.

Authors:  Wenyi Wei; William G Kaelin
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

2.  COP1 is a tumour suppressor that causes degradation of ETS transcription factors.

Authors:  Alberto C Vitari; Kevin G Leong; Kim Newton; Cindy Yee; Karen O'Rourke; Jinfeng Liu; Lilian Phu; Rajesh Vij; Ronald Ferrando; Suzana S Couto; Sankar Mohan; Ajay Pandita; Jo-Anne Hongo; David Arnott; Ingrid E Wertz; Wei-Qiang Gao; Dorothy M French; Vishva M Dixit
Journal:  Nature       Date:  2011-05-15       Impact factor: 49.962

Review 3.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

4.  COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Authors:  David Dornan; Sheila Bheddah; Kim Newton; William Ince; Gretchen D Frantz; Patrick Dowd; Hartmut Koeppen; Vishva M Dixit; Dorothy M French
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 5.  Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression.

Authors:  A Jones; J Crew
Journal:  Urol Clin North Am       Date:  2000-02       Impact factor: 2.241

Review 6.  Spotlight on the role of COP1 in tumorigenesis.

Authors:  Jean-Christophe Marine
Journal:  Nat Rev Cancer       Date:  2012-06-07       Impact factor: 60.716

7.  Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.

Authors:  Marco Oderda; Fulvio Ricceri; Francesca Pisano; Chiara Fiorito; Alberto Gurioli; Giovanni Casetta; Andrea Zitella; Donatella Pacchioni; Paolo Gontero
Journal:  Urol Int       Date:  2013-01-17       Impact factor: 2.089

8.  The ubiquitin ligase COP1 is a critical negative regulator of p53.

Authors:  David Dornan; Ingrid Wertz; Harumi Shimizu; David Arnott; Gretchen D Frantz; Patrick Dowd; Karen O'Rourke; Hartmut Koeppen; Vishva M Dixit
Journal:  Nature       Date:  2004-04-21       Impact factor: 49.962

9.  Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests.

Authors:  Vinata B Lokeshwar; Grethchen L Schroeder; Marie G Selzer; Stefan H Hautmann; J Timothy Posey; Robert C Duncan; Roger Watson; Lyndon Rose; Steven Markowitz; Mark S Soloway
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  4 in total

1.  COP1 Acts as a Ubiquitin Ligase for PCDH9 Ubiquitination and Degradation in Human Glioma.

Authors:  Kunlin Zhou; Lei Wang; Zhiyuan Sun; Yuelin Liu; Yufu Zhu; Zhiyi Liu; Bin Zhang; Hengliang Shi
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

Review 2.  Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.

Authors:  Sanam Sane; Khosrow Rezvani
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

3.  Imaging and kinetics of the bimolecular complex formed by the tumor suppressor p53 with ubiquitin ligase COP1 as studied by atomic force microscopy and surface plasmon resonance.

Authors:  Ilaria Moscetti; Anna Rita Bizzarri; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2018-01-04

Review 4.  Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.

Authors:  Scott Bang; Sandeep Kaur; Manabu Kurokawa
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.